| Title |
Application of bee venom and its main constituent melittin for cancer treatment
|
|---|---|
| Published in |
Cancer Chemotherapy and Pharmacology, September 2016
|
| DOI | 10.1007/s00280-016-3160-1 |
| Pubmed ID | |
| Authors |
Cui-cui Liu, Ding-jun Hao, Qian Zhang, Jing An, Jing-jing Zhao, Bo Chen, Ling-ling Zhang, Hao Yang |
| Abstract |
Bee venom and its main constituent melittin (MEL) have been extensively studied in the treatment of tumors. However, the non-specific cytotoxicity and hemolytic activity have hampered the clinical application. Currently, a number of research groups have reported a series of optimization strategies, including gene therapy, recombinant immunotoxin incorporating MEL or MEL nanoparticles, targeting tumor cells to attenuate the cytotoxicity and improve its antitumor efficiency and therapeutic capabilities, which have shown very promising in overcoming some of these obstacles. In this review, we summarize the current knowledge regarding anticancer effects of bee venom and its main compound MEL on different kinds of tumor cells as well as elucidate their possible anticancer mechanisms. It could be concluded that MEL exerts multiple effects on cellular functions of cancerous cells such as proliferation, apoptosis, metastasis, angiogenesis as well as cell cycle, and the anticancer processes involve diverse signal molecules and regulatory pathways. We also highlight the recent research progress for efficient delivery of MEL peptide, thus providing new ideas and hopeful strategies for the in vivo application of MEL. |
Mendeley readers
The data shown below were compiled from readership statistics for 117 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Sweden | 1 | <1% |
| Unknown | 116 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 17 | 15% |
| Student > Bachelor | 11 | 9% |
| Student > Ph. D. Student | 9 | 8% |
| Researcher | 8 | 7% |
| Student > Doctoral Student | 8 | 7% |
| Other | 16 | 14% |
| Unknown | 48 | 41% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 23 | 20% |
| Agricultural and Biological Sciences | 14 | 12% |
| Chemistry | 10 | 9% |
| Medicine and Dentistry | 6 | 5% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 3% |
| Other | 7 | 6% |
| Unknown | 54 | 46% |
Attention Score in Context
This research output has an Altmetric Attention Score of 21. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 July 2023.
All research outputs
#1,577,463
of 23,815,455 outputs
Outputs from Cancer Chemotherapy and Pharmacology
#29
of 2,501 outputs
Outputs of similar age
#29,152
of 325,433 outputs
Outputs of similar age from Cancer Chemotherapy and Pharmacology
#1
of 28 outputs
Altmetric has tracked 23,815,455 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,501 research outputs from this source. They receive a mean Attention Score of 4.1. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 325,433 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 28 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 96% of its contemporaries.